(2024-2033) Calcium Channel Blocker Market Size, Share, Trends, Industry Growth Analysis and Forecast | Pfizer Inc., GlaxoSmithKline PLC, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc

Overview and Scope
Calcium channel blockers refer to a type of drug that prevents calcium from entering the muscle cells of the heart and blood vessels. Calcium channel blockers are used to treat a variety of disorders, including high blood pressure, angina, and irregular heartbeats.

Sizing and Forecast

The calcium channel blocker market size has grown strongly in recent years. It will grow from $14.72 billion in 2023 to $15.75 billion in 2024 at a compound annual growth rate (CAGR) of 7.0%.  The  growth in the historic period can be attributed to increased incidence of cardiovascular diseases, aging population, advancements in medical research, changing lifestyles, increased awareness.

The calcium channel blocker market size is expected to see strong growth in the next few years. It will grow to $20.64 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%.  The growth in the forecast period can be attributed to rising global burden of cardiovascular diseases, personalized medicine trends, increased access to healthcare, expansion of indications, regulatory approvals and market expansions. Major trends in the forecast period include market growth, technological advancements, regulatory landscape, competitive analysis, patient preferences and awareness.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

The calcium channel blocker market covered in this report is segmented –

1) By Drug Class: Dihydropyridine, Benzothizepine, Phenylalkylamine, Other Drug Classes
2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

North America was the largest region in the calcium channel blocker market in 2023. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample_request?id=9428&type=smp

Major Driver Impacting Market Growth

The increasing prevalence rate of cardiovascular diseases is expected to boost the growth of the calcium channel blocker market going forward. Cardiovascular disease refers to a type of condition that affects the heart or blood vessels. Calcium channel blockers (CCBs) are used to lower the risk of heart failure and stroke. Hence, the increasing prevalence rate of cardiovascular diseases will result in a rise in demand for the calcium channel blockers. For instance, in August 2022, according to a report published by the American College of Cardiology, a US-based non-profit medical association, In the United States, it is anticipated that all four cardiovascular risk factors will increase between 2025 and 2060. The largest percentage rise is expected in diabetes, with a 39.3% increase to 55 million individuals, followed by dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). The researchers also observed that the most substantial projected increases in cardiovascular disease rates were for stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), followed by ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million).  Therefore, the increasing prevalence rate of cardiovascular diseases is driving the growth of the calcium channel blocker market.

Key Industry Players

Major companies operating in the calcium channel blocker market are developing innovative products such as tablets for pulmonary arterial hypertension to meet larger customer bases, more sales, and increase revenue. In the context of Pulmonary Arterial Hypertension (PAH), a tablet refers to an oral pharmaceutical formulation designed for the treatment of this specific medical condition. For instance, in May 2022, Zydus, an India-based pharmaceutical company, announced the US Food and Drug Administration (FDA) approval for Selexipag tablets. Selexipag is prescribed in adults to manage Pulmonary Arterial Hypertension (PAH), aiming to delay the progression of the disease and minimize the likelihood of hospitalization associated with PAH. This medication functions as a prostacyclin receptor agonist.

The calcium channel blocker market report table of contents includes:

1. Executive Summary

2. Calcium Channel Blocker Characteristics

3. Calcium Channel Blocker Trends And Strategies

4. Calcium Channel Blocker – Macro Economic Scenario

5. Global Calcium Channel Blocker Size and Growth

…..

32. Global Calcium Channel Blocker Competitive Benchmarking

33. Global Calcium Channel Blocker Competitive Dashboard

34. Key Mergers And Acquisitions In The Calcium Channel Blocker

35. Calcium Channel Blocker Future Outlook and Potential Analysis

36. Appendix

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model